icon-folder.gif   Conference Reports for NATAP  
 
  62th Annual Meeting of the American Association for the Study of Liver Diseases San Francisco 2011 Nov 6-9 Back grey_arrow_rt.gif
 
 
 
High sustained virologic response (SVR24) rates with response-guided danoprevir (DNV; RG7227) plus PegIFN alfa-2a (40KD) and ribavirin (P/R) in treatment-naive HCV genotype 1 (G1) patients: results from the ATLAS study
 
 
  Reported by Jules Levin AASLD Nov 5-9 2011 SF
 
Norah Terrault, Curtis Cooper, Luis A Balart, Dominique G Larrey, Terry D Box, Eric Yoshida, Eric Lawitz, Peter Buggisch, Peter Ferenci, Martin Weltman, Emily Labriola-Tompkins, Sophie Le Pogam, Isabel Najera, Denise Thomas, Greg Hooper, Nancy Shulman, Ying Zhang, Mercidita T Navarro, Chin Yin Lim, Ellen S Yetzer, Patrick Marcellin
 
From Jules: danoprevir is being developed being boosted by low dose, 100 mg, of ritonavir as are HIV protease inhibitors, and study results will be presented soon at a conference.

AASLD1.gif

AASLD2.gif

AASLD3.gif

AASLD4.gif

AASLD5.gif

AASLD6.gif

AASLD7.gif

AASLD8.gif

AASLD9.gif